These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

312 related articles for article (PubMed ID: 30927251)

  • 1. Recurrent moderate-risk mutations in Finnish breast and ovarian cancer patients.
    Nurmi A; Muranen TA; Pelttari LM; Kiiski JI; Heikkinen T; Lehto S; Kallioniemi A; Schleutker J; Bützow R; Blomqvist C; Aittomäki K; Nevanlinna H
    Int J Cancer; 2019 Nov; 145(10):2692-2700. PubMed ID: 30927251
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of Population-Based BRCA1, BRCA2, RAD51C, RAD51D, BRIP1, PALB2 Mutation Testing in Unselected General Population Women.
    Manchanda R; Patel S; Gordeev VS; Antoniou AC; Smith S; Lee A; Hopper JL; MacInnis RJ; Turnbull C; Ramus SJ; Gayther SA; Pharoah PDP; Menon U; Jacobs I; Legood R
    J Natl Cancer Inst; 2018 Jul; 110(7):714-725. PubMed ID: 29361001
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gene panel testing of 5589 BRCA1/2-negative index patients with breast cancer in a routine diagnostic setting: results of the German Consortium for Hereditary Breast and Ovarian Cancer.
    Hauke J; Horvath J; Groß E; Gehrig A; Honisch E; Hackmann K; Schmidt G; Arnold N; Faust U; Sutter C; Hentschel J; Wang-Gohrke S; Smogavec M; Weber BHF; Weber-Lassalle N; Weber-Lassalle K; Borde J; Ernst C; Altmüller J; Volk AE; Thiele H; Hübbel V; Nürnberg P; Keupp K; Versmold B; Pohl E; Kubisch C; Grill S; Paul V; Herold N; Lichey N; Rhiem K; Ditsch N; Ruckert C; Wappenschmidt B; Auber B; Rump A; Niederacher D; Haaf T; Ramser J; Dworniczak B; Engel C; Meindl A; Schmutzler RK; Hahnen E
    Cancer Med; 2018 Apr; 7(4):1349-1358. PubMed ID: 29522266
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association Between Loss-of-Function Mutations Within the FANCM Gene and Early-Onset Familial Breast Cancer.
    Neidhardt G; Hauke J; Ramser J; Groß E; Gehrig A; Müller CR; Kahlert AK; Hackmann K; Honisch E; Niederacher D; Heilmann-Heimbach S; Franke A; Lieb W; Thiele H; Altmüller J; Nürnberg P; Klaschik K; Ernst C; Ditsch N; Jessen F; Ramirez A; Wappenschmidt B; Engel C; Rhiem K; Meindl A; Schmutzler RK; Hahnen E
    JAMA Oncol; 2017 Sep; 3(9):1245-1248. PubMed ID: 28033443
    [TBL] [Abstract][Full Text] [Related]  

  • 5. About 1% of the breast and ovarian Spanish families testing negative for BRCA1 and BRCA2 are carriers of RAD51D pathogenic variants.
    Gutiérrez-Enríquez S; Bonache S; de Garibay GR; Osorio A; Santamariña M; Ramón y Cajal T; Esteban-Cardeñosa E; Tenés A; Yanowsky K; Barroso A; Montalban G; Blanco A; Cornet M; Gadea N; Infante M; Caldés T; Díaz-Rubio E; Balmaña J; Lasa A; Vega A; Benítez J; de la Hoya M; Diez O
    Int J Cancer; 2014 May; 134(9):2088-97. PubMed ID: 24130102
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selected Aspects of Molecular Diagnostics of Constitutional Alterations in BRCA1 and BRCA2 Genes Associated with Increased Risk of Breast Cancer in the Polish Population.
    Górski B
    Hered Cancer Clin Pract; 2006 Aug; 4(3):142-52. PubMed ID: 20223018
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical Actionability of Multigene Panel Testing for Hereditary Breast and Ovarian Cancer Risk Assessment.
    Desmond A; Kurian AW; Gabree M; Mills MA; Anderson MJ; Kobayashi Y; Horick N; Yang S; Shannon KM; Tung N; Ford JM; Lincoln SE; Ellisen LW
    JAMA Oncol; 2015 Oct; 1(7):943-51. PubMed ID: 26270727
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gene panel sequencing in familial breast/ovarian cancer patients identifies multiple novel mutations also in genes others than BRCA1/2.
    Kraus C; Hoyer J; Vasileiou G; Wunderle M; Lux MP; Fasching PA; Krumbiegel M; Uebe S; Reuter M; Beckmann MW; Reis A
    Int J Cancer; 2017 Jan; 140(1):95-102. PubMed ID: 27616075
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gene-panel testing of breast and ovarian cancer patients identifies a recurrent RAD51C duplication.
    Pelttari LM; Shimelis H; Toiminen H; Kvist A; Törngren T; Borg Å; Blomqvist C; Bützow R; Couch F; Aittomäki K; Nevanlinna H
    Clin Genet; 2018 Mar; 93(3):595-602. PubMed ID: 28802053
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pathogenic and likely pathogenic variants in PALB2, CHEK2, and other known breast cancer susceptibility genes among 1054 BRCA-negative Hispanics with breast cancer.
    Weitzel JN; Neuhausen SL; Adamson A; Tao S; Ricker C; Maoz A; Rosenblatt M; Nehoray B; Sand S; Steele L; Unzeitig G; Feldman N; Blanco AM; Hu D; Huntsman S; Castillo D; Haiman C; Slavin T; Ziv E
    Cancer; 2019 Aug; 125(16):2829-2836. PubMed ID: 31206626
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The clinical importance of a genetic analysis of moderate-risk cancer susceptibility genes in breast and other cancer patients from the Czech Republic].
    Pohlreich P; Kleibl Z; Kleiblová P; Janatová M; Soukupová J; Macháčková E; Házová J; Vašíčková P; Sťahlová Hrabincová E; Navrátilová M; Svoboda M; Foretová L
    Klin Onkol; 2012; 25 Suppl():S59-66. PubMed ID: 22920209
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer.
    Walsh T; Casadei S; Coats KH; Swisher E; Stray SM; Higgins J; Roach KC; Mandell J; Lee MK; Ciernikova S; Foretova L; Soucek P; King MC
    JAMA; 2006 Mar; 295(12):1379-88. PubMed ID: 16551709
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The frequency of cancer predisposition gene mutations in hereditary breast and ovarian cancer patients in Taiwan: From BRCA1/2 to multi-gene panels.
    Sung PL; Wen KC; Chen YJ; Chao TC; Tsai YF; Tseng LM; Qiu JT; Chao KC; Wu HH; Chuang CM; Wang PH; Huang CF
    PLoS One; 2017; 12(9):e0185615. PubMed ID: 28961279
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recommendations for Preventive Care for Women with Rare Genetic Cause of Breast and Ovarian Cancer.
    Foretová L; Navrátilová M; Svoboda M; Vašíčková P; Sťahlová EH; Házová J; Kleiblová P; Kleibl Z; Macháčková E; Palácová M; Petráková K
    Klin Onkol; 2019; 32(Supplementum2):6-13. PubMed ID: 31409076
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BRCA1 and BRCA2 mutations in males with familial breast and ovarian cancer syndrome. Results of a Spanish multicenter study.
    de Juan I; Palanca S; Domenech A; Feliubadaló L; Segura Á; Osorio A; Chirivella I; de la Hoya M; Sánchez AB; Infante M; Tena I; Díez O; Garcia-Casado Z; Vega A; Teulé À; Barroso A; Pérez P; Durán M; Carrasco E; Juan-Fita MJ; Murria R; Llop M; Barragan E; Izquierdo Á; Benítez J; Caldés T; Salas D; Bolufer P
    Fam Cancer; 2015 Dec; 14(4):505-13. PubMed ID: 26026974
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Finnish founder mutation in RAD51D: analysis in breast, ovarian, prostate, and colorectal cancer.
    Pelttari LM; Kiiski J; Nurminen R; Kallioniemi A; Schleutker J; Gylfe A; Aaltonen LA; Leminen A; Heikkilä P; Blomqvist C; Bützow R; Aittomäki K; Nevanlinna H
    J Med Genet; 2012 Jul; 49(7):429-32. PubMed ID: 22652533
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Contribution of RAD51D germline mutations in breast and ovarian cancer in Greece.
    Konstanta I; Fostira F; Apostolou P; Stratikos E; Kalfakakou D; Pampanos A; Kollia P; Papadimitriou C; Konstantopoulou I; Yannoukakos D
    J Hum Genet; 2018 Nov; 63(11):1149-1158. PubMed ID: 30111881
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Statewide Retrospective Review of Familial Pancreatic Cancer in Delaware, and Frequency of Genetic Mutations in Pancreatic Cancer Kindreds.
    Catts ZA; Baig MK; Milewski B; Keywan C; Guarino M; Petrelli N
    Ann Surg Oncol; 2016 May; 23(5):1729-35. PubMed ID: 26727920
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Genotyping of BRCA1, BRCA2 and CHEK2 germline mutations in Russian breast cancer patients using diagnostic biochips].
    Nasedkina TV; Gromyko OE; Emel'ianova MA; Ignatova EO; Kazubskaia TP; Portnoĭ SM; Zasedatelev AS; Liubchenko LN
    Mol Biol (Mosk); 2014; 48(2):243-50. PubMed ID: 25850293
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevalence of BRCA1/2 germline mutations in 21 401 families with breast and ovarian cancer.
    Kast K; Rhiem K; Wappenschmidt B; Hahnen E; Hauke J; Bluemcke B; Zarghooni V; Herold N; Ditsch N; Kiechle M; Braun M; Fischer C; Dikow N; Schott S; Rahner N; Niederacher D; Fehm T; Gehrig A; Mueller-Reible C; Arnold N; Maass N; Borck G; de Gregorio N; Scholz C; Auber B; Varon-Manteeva R; Speiser D; Horvath J; Lichey N; Wimberger P; Stark S; Faust U; Weber BH; Emons G; Zachariae S; Meindl A; Schmutzler RK; Engel C;
    J Med Genet; 2016 Jul; 53(7):465-71. PubMed ID: 26928436
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.